Treatment for Blood Clots in the Veins of the Legs
Completed
National Institutes of Health Clinical Center (CC)
Phase 1
1998-02-01
Acute deep venous thrombosis (ADVT) of the lower extremity is a common disorder. Traditional
treatment with anticoagulation therapy is effective in reducing the associated risk of
pulmonary embolism, but is ineffective in restoring patency of the venous system of the lower
extremity. While systemic thrombolytic therapy has been shown to be more effective than
anticoagulation, catheter directed local thrombolytic therapy is the most effective treatment
in restoring venous patency. Current treatment regimens are based on use of urokinase,
infused continuously through catheters imbedded into the thrombus. These treatment regimens
require doses on the order of 10,000,000 units of urokinase, resulting in significant
bleeding complications and prohibitive costs.
Experience at NIH with pulse-spray treatment of axillary subclavian venous thrombosis with
rtPA indicates that this is a highly effective and safe alternative thrombolytic regimen. The
proposed protocol is designed to evaluate the efficiency, safety, and doses of rtPA
associated with pulse spray directed rtPA treatment of the more extensive venous thrombosis
encountered in the lower extremity.
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Completed
United States Department of Defense
Phase 1
2004-05-01
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine
in patients with advanced malignancies.
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Completed
Heidelberg Pharma AG
Phase 1
2004-05-01
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine
in patients with advanced malignancies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.